PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

1
Player Avatar FoxForce5contest (34.00) Submitted: 8/18/2012 9:18:30 PM : Outperform Start Price: $6.82 PDLI Score: -2.25

on 8-18-12 Momentum21 picked PDLI

Report this Post 5 Replies
Member Avatar FoxForce5contest (34.00) Submitted: 8/22/2012 3:51:21 AM
Recs: 0

at $7.38

Report this Post
Member Avatar HarryCarysGhost (99.78) Submitted: 9/6/2012 8:39:15 PM
Recs: 0

Booyah! MOMO siezes the momentum with a .15 div on 9/06./12 lowering the start price to $7.23.

Report this Post
Member Avatar HarryCarysGhost (99.78) Submitted: 12/5/2012 8:28:59 PM
Recs: 0

PDL Bio announces 2nd stage dividend results-
.14 divi lowering the start price to $7.09.

Report this Post
Member Avatar HarryCarysGhost (99.78) Submitted: 3/20/2013 8:24:24 PM
Recs: 0

3rd stage dividend results are in, .15 divi lowering the start price to $6.94.

Report this Post
Member Avatar HarryCarysGhost (99.78) Submitted: 6/15/2013 7:28:59 PM
Recs: 0

4th stage dividend results are in-
$6.82
(awaiting fda approval for inevitable run up in price)

Report this Post

Featured Broker Partners


Advertisement